High Doses of Romiplostim Induce Proliferation and Reduce Proplatelet Formation by Human Megakaryocytes

BACKGROUND: Romiplostim (AMG531) is a Thrombopoietin (TPO) receptor agonist with no homology with the endogenous TPO that has been used to treat patients affected by immune thrombocytopenia (ITP). Despite the use of TPO mimetics in the clinical practice, the mechanisms underlying their impact on meg...

Descripción completa

Detalles Bibliográficos
Autores principales: Currao, Manuela, Balduini, Carlo L., Balduini, Alessandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554640/
https://www.ncbi.nlm.nih.gov/pubmed/23359807
http://dx.doi.org/10.1371/journal.pone.0054723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3554640/
https://www.ncbi.nlm.nih.gov/pubmed/23359807
http://dx.doi.org/10.1371/journal.pone.0054723

Ejemplares similares